Zymeron Corp.
Zymeron is a research-based biotechnology company dedicated to developing innovative technologies and products to improve health outcomes. They focus on proactive health solutions, including myeloprotective drugs, rapid diagnostics, and drug delivery systems, with a mission to deliver step-change performance and disruptive innovations in healthcare.
Industries
Nr. of Employees
small (1-50)
Zymeron Corp.
400 Park Offices Drive, STE 211, PO Box 12072, Research Triangle Park, NC 27709
Patents
Immunoassay platform for the serological discrimination of closely related viruses
US-12196755-B2
View Details
Immunoassay platform for the serological discrimination of closely related viruses
US-12196755-B2
View DetailsProducts
Bone marrow-targeted myeloprotective therapeutic (preclinical)
Preclinical injectable drug program that delivers cytoprotective molecules to hematopoietic stem and progenitor cells to prevent chemotherapy- or radiation-induced myelosuppression.
Rapid lab-on-chip sterility testing system (rapid microbiological method)
Automated, closed-system lab-on-chip sterility test providing qualitative presence/absence results in under 30 minutes with single-cell sensitivity and non-destructive sample handling.
Long-acting subcutaneous prophylactic drug implant (preclinical)
Biodegradable subcutaneous implant technology intended to provide customizable-duration prophylaxis (1–12 months) for infectious disease prevention without requiring surgical removal.
Dual biologic–small molecule wound therapeutics
Extracellular vesicle-based wound therapy program for biofilm management, antimicrobial activity, and wound healing promotion, developed with companion diagnostic and sterility testing components.
Bone marrow-targeted myeloprotective therapeutic (preclinical)
Preclinical injectable drug program that delivers cytoprotective molecules to hematopoietic stem and progenitor cells to prevent chemotherapy- or radiation-induced myelosuppression.
Rapid lab-on-chip sterility testing system (rapid microbiological method)
Automated, closed-system lab-on-chip sterility test providing qualitative presence/absence results in under 30 minutes with single-cell sensitivity and non-destructive sample handling.
Long-acting subcutaneous prophylactic drug implant (preclinical)
Biodegradable subcutaneous implant technology intended to provide customizable-duration prophylaxis (1–12 months) for infectious disease prevention without requiring surgical removal.
Dual biologic–small molecule wound therapeutics
Extracellular vesicle-based wound therapy program for biofilm management, antimicrobial activity, and wound healing promotion, developed with companion diagnostic and sterility testing components.
Services
Development services to convert oral or insoluble small molecules into injectable formulations and to pursue reformulation-based regulatory pathways.
Small-scale production services for test reagents and test strips using automated dispensing to support deployable manufacturing.
Joint development engagements with academic, government, and commercial partners for funded R&D and commercialization.
Development services to convert oral or insoluble small molecules into injectable formulations and to pursue reformulation-based regulatory pathways.
Small-scale production services for test reagents and test strips using automated dispensing to support deployable manufacturing.
Joint development engagements with academic, government, and commercial partners for funded R&D and commercialization.
Expertise Areas
- Myeloprotection and chemoprotection
- Bone marrow-targeted drug delivery
- Injectable formulation and reformulation
- Long-acting implantable drug delivery
Key Technologies
- Peptide drug conjugates for targeted delivery
- Extracellular vesicle-mediated delivery
- Lab-on-chip microfluidics
- Miniaturized automated instrumentation
News & Updates
Zymeron announced its relocation to the Frontier Campus Building 400, Research Triangle Park, NC, expanding its capabilities in rapid diagnostic tests and drug discovery.
Zymeron announced that its myelotoxicity drug program is boosted by a $3.0M federal funding to advance its lead drug candidate in preclinical studies.
Zymeron received multi-year funding from the Department of Defense to develop long-lasting antimalaria prophylactic drug implants.
Zymeron announced its relocation to the Frontier Campus Building 400, Research Triangle Park, NC, expanding its capabilities in rapid diagnostic tests and drug discovery.
Zymeron announced that its myelotoxicity drug program is boosted by a $3.0M federal funding to advance its lead drug candidate in preclinical studies.
Zymeron received multi-year funding from the Department of Defense to develop long-lasting antimalaria prophylactic drug implants.